Reimagining prostate cancer screening: the IMPACT of germline mutations
Menée auprès de 644 hommes présentant des variants pathogènes au niveau des gènes impliqués dans le système de réparation des mésappariements de l'ADN et menée auprès de 184 témoins, cette étude internationale évalue l'utilité, du point de vue de l'incidence du cancer de la prostate, d'un programme de dépistage par dosage du PSA puis par biopsie si le niveau sérique du PSA est supérieur à 3ng/ml
Structured prostate-specific antigen (PSA) screening allows for the early detection of prostate cancer in men aged 55–69 years with a reduction in the incidence of metastatic disease at presentation and cancer-specific mortality at 16 year's follow-up. 1Population-based screening has been associated with a non-negligible risk of overdiagnosis (ie, the detection of cancers that would not have caused symptoms), which can be as high as 40%, and has limited its adoption at a large scale 2such that no national prostate cancer screening programmes exist in the USA and Europe. Restricting the use of repeated PSA testing to men at risk of early-onset disease because of a family history of prostate cancer or germline mutations has been proposed as a means of improving the effectiveness of screening.
The Lancet Oncology , commentaire en libre accès, 2020